株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

原発性胆汁性胆管炎(PBC) - 市場洞察、疫学、市場予測 2028年

Primary Biliary Cholangitis - Market Insights, Epidemiology and Market Forecast 2028

発行 DelveInsight Business Research LLP 商品コード 773915
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.78円で換算しております。
Back to Top
原発性胆汁性胆管炎(PBC) - 市場洞察、疫学、市場予測 2028年 Primary Biliary Cholangitis - Market Insights, Epidemiology and Market Forecast 2028
出版日: 2019年01月01日 ページ情報: 英文 100 Pages
概要

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の原発性胆汁性胆管炎(PBC)市場を調査し、疾病の概要や現行の治療法、新薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、有病数・罹患数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 イントロダクション

第2章 原発性胆汁性胆管炎(PBC)市場の概要

  • 原発性胆汁性胆管炎(PBC)の市場シェア(実績値)
  • 原発性胆汁性胆管炎(PBC)の市場シェア(予測値)

第3章 疾病背景と概要:原発性胆汁性胆管炎(PBC)

  • イントロダクション
  • 症状
  • 病因
  • 危険因子
  • 病態生理学
  • 診断
  • 治療

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の原発性胆汁性胆管炎(PBC)の総有病数/罹患数
  • 主要7カ国の原発性胆汁性胆管炎(PBC)の総有病数:国別

第5章 原発性胆汁性胆管炎(PBC)の疫学:国別

  • 米国
    • 仮定と理論的根拠
    • 原発性胆汁性胆管炎(PBC)有病数/罹患数
    • 原発性胆汁性胆管炎(PBC)の症例数:病型別
    • 原発性胆汁性胆管炎(PBC)の症例数:性別
    • 原発性胆汁性胆管炎(PBC)の診断数
    • 原発性胆汁性胆管炎(PBC)の治療可能な症例数
  • EU5カ国
    • 仮定と理論的根拠
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第6章 現行治療

  • 治療アルゴリズム
  • 治療ガイドライン

第7章 アンメットニーズ

第8章 上市済み治療薬

  • 医薬品 A:製薬企業
    • 医薬品概要
    • 作用機序
    • 規制のマイルストーン
    • 長所と短所
    • 製品プロファイル
  • 医薬品 B:製薬企業

第9章 パイプライン治療薬

第10章 キークロスコンペティション

第11章 原発性胆汁性胆管炎(PBC)の新薬

  • 医薬品 C:製薬企業
    • 薬の説明
    • 臨床試験の詳細
    • 安全性と有効性のプロファイル
    • 長所と短所
    • パイプライン開発活動
    • 製品プロファイル
  • 医薬品 D:製薬企業

第12章 原発性胆汁性胆管炎(PBC):主要7カ国の市場分析

  • 原発性胆汁性胆管炎(PBC)の市場規模
  • 原発性胆汁性胆管炎(PBC)の上市済み治療薬のシェア
  • 原発性胆汁性胆管炎(PBC)治療薬の売上:製品別

第13章 原発性胆汁性胆管炎(PBC):国別市場分析

  • 米国
    • 原発性胆汁性胆管炎(PBC)の市場規模
    • 原発性胆汁性胆管炎(PBC)上市済み治療薬の市場シェア
    • 原発性胆汁性胆管炎(PBC)治療薬の売上:製品別
    • 新薬の分析と市場への影響
  • EU5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第14章 市場成長要因

第15章 市場の障壁

第16章 付録

第17章 調査方法

  • 出典

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Primary biliary cholangitis in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Primary biliary cholangitis in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Primary biliary cholangitis in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Primary biliary cholangitis in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Primary biliary cholangitis in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Primary biliary cholangitis in United States (2016-2028)
  • Table 7: Treatable Cases of the Primary biliary cholangitis in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Primary biliary cholangitis in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Primary biliary cholangitis in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Primary biliary cholangitis in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Primary biliary cholangitis in Germany (2016-2028)
  • Table 12: Treatable Cases of the Primary biliary cholangitis in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Primary biliary cholangitis in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Primary biliary cholangitis in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Primary biliary cholangitis in France (2016-2028)
  • Table 16: Diagnosed Cases of the Primary biliary cholangitis in France (2016-2028)
  • Table 17: Treatable Cases of the Primary biliary cholangitis in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Primary biliary cholangitis in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Primary biliary cholangitis in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Primary biliary cholangitis in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Primary biliary cholangitis in Italy (2016-2028)
  • Table 22: Treatable Cases of the Primary biliary cholangitis in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Primary biliary cholangitis in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Primary biliary cholangitis in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Primary biliary cholangitis in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Primary biliary cholangitis in Spain (2016-2028)
  • Table 27: Treatable Cases of the Primary biliary cholangitis in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Primary biliary cholangitis in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Primary biliary cholangitis in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Primary biliary cholangitis in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Primary biliary cholangitis in UK (2016-2028)
  • Table 32: Treatable Cases of the Primary biliary cholangitis in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Primary biliary cholangitis in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Primary biliary cholangitis in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Primary biliary cholangitis in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Primary biliary cholangitis in Japan (2016-2028)
  • Table 37: Treatable Cases of the Primary biliary cholangitis in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Table 42:7MM- Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Table 45: United States-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Table 48: Germany-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Table 51: France-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Table 54: Italy-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Table 57: Spain-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 59: UK-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Table 60: UK-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 61: UK-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Table 63: Japan-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Primary biliary cholangitis in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Primary biliary cholangitis in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Primary biliary cholangitis in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Primary biliary cholangitis in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Primary biliary cholangitis in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Primary biliary cholangitis in United States (2016-2028)
  • Figure 7: Treatable Cases of the Primary biliary cholangitis in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Primary biliary cholangitis in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Primary biliary cholangitis in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Primary biliary cholangitis in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Primary biliary cholangitis in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Primary biliary cholangitis in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Primary biliary cholangitis in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Primary biliary cholangitis in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Primary biliary cholangitis in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Primary biliary cholangitis in France (2016-2028)
  • Figure 17: Treatable Cases of the Primary biliary cholangitis in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Primary biliary cholangitis in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Primary biliary cholangitis in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Primary biliary cholangitis in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Primary biliary cholangitis in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Primary biliary cholangitis in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Primary biliary cholangitis in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Primary biliary cholangitis in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Primary biliary cholangitis in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Primary biliary cholangitis in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Primary biliary cholangitis in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Primary biliary cholangitis in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Primary biliary cholangitis in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Primary biliary cholangitis in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Primary biliary cholangitis in UK (2016-2028)
  • Figure 32: Treatable Cases of the Primary biliary cholangitis in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Primary biliary cholangitis in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Primary biliary cholangitis in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Primary biliary cholangitis in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Primary biliary cholangitis in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Primary biliary cholangitis in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Figure 45: United States-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Figure 51: France-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 59: UK-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Figure 60: UK-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 61: UK-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Primary biliary cholangitis in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Primary biliary cholangitis by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Primary biliary cholangitis by Therapies in USD MM (2016-2028)
目次
Product Code: DIMI0489

DelveInsight's "Primary biliary cholangitis - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Primary biliary cholangitis epidemiology and market outlook for the 7MM.

Primary biliary cholangitis (PBC) is an autoimmune, slowly progressive, cholestatic, liver disease characterized by a triad of chronic cholestasis, circulating anti-mitochondrial antibodies (AMA), and characteristic liver biopsy findings of nonsuppurative destructive cholangitis and interlobular bile duct destruction. PBC is most frequently a disease of women and occurs between the fourth and sixth decades of life. Primary biliary cholangitis is considered an autoimmune disease, which means that the body's immune system is mistakenly attacking healthy cells and tissue. It usually develops slowly. Medication can slow liver damage, especially if treatment begins early.

Bile is a liquid produced inside the liver that's used to help digest fats and remove waste products from the body. It passes out of the liver through small tubes called bile ducts. In PBC, the immune system (the body's natural defense against infection and illness) mistakenly attacks the bile ducts. It's not clear why this happens, but it's thought to be caused by a combination of subtle differences in how the immune system works. The bile ducts become damaged and injured, causing bile to build up in the liver. This further damages the liver and may lead to scarring (cirrhosis).

Markets Covered:

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Understanding and Treatment Algorithm:

The market report provides the overview of the Primary biliary cholangitis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Epidemiology:

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Primary biliary cholangitis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Product Profiles & Analysis:

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Market Outlook:

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Primary biliary cholangitis market.

Market Share by Therapies:

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Report Insights:

  • Patient Population in Primary biliary cholangitis
  • Therapeutic Approaches in Primary biliary cholangitis
  • Primary biliary cholangitis Pipeline Analysis
  • Primary biliary cholangitis Market Size and Trends
  • Primary biliary cholangitis Market Opportunities
  • Impact of upcoming Therapies in Primary biliary cholangitis

Report Key Strengths:

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Report Assessment:

  • Current Treatment Practices in Primary biliary cholangitis
  • Unmet Needs in Primary biliary cholangitis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Primary biliary cholangitis market
  • Organize sales and marketing efforts by identifying the best opportunities for Primary biliary cholangitis market
  • To understand the future market competition in the Primary biliary cholangitis market.

Table of Contents

1. Report Introduction

2. Primary biliary cholangitis Market Overview at a Glance

  • 2.1. Market Share Distribution of Primary biliary cholangitis in 2016
  • 2.2. Market Share Distribution of Primary biliary cholangitis in 2028

3. Disease Background and Overview: Primary biliary cholangitis

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Primary biliary cholangitis in 7MM
  • 4.3. Total Prevalent Patient Population of Primary biliary cholangitis in 7MM - By Countries

5. Epidemiology of Primary biliary cholangitis by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Primary biliary cholangitis
    • 5.1.3. Sub-Type Specific cases of the Primary biliary cholangitis *
    • 5.1.4. Sex- Specific Cases of the Primary biliary cholangitis *
    • 5.1.5. Diagnosed Cases of the Primary biliary cholangitis
    • 5.1.6. Treatable Cases of the Primary biliary cholangitis
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Primary biliary cholangitis
    • 5.4.3. Sub-Type Specific cases of the Primary biliary cholangitis *
    • 5.4.4. Sex- Specific Cases of the Primary biliary cholangitis *
    • 5.4.5. Diagnosed Cases of the Primary biliary cholangitis
    • 5.4.6. Treatable Cases of the Primary biliary cholangitis
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Primary biliary cholangitis
    • 5.5.3. Sub-Type Specific cases of the Primary biliary cholangitis *
    • 5.5.4. Sex- Specific Cases of the Primary biliary cholangitis *
    • 5.5.5. Diagnosed Cases of the Primary biliary cholangitis
    • 5.5.6. Treatable Cases of the Primary biliary cholangitis
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Primary biliary cholangitis
    • 5.6.3. Sub-Type Specific cases of the Primary biliary cholangitis *
    • 5.6.4. Sex- Specific Cases of the Primary biliary cholangitis *
    • 5.6.5. Diagnosed Cases of the Primary biliary cholangitis
    • 5.6.6. Treatable Cases of the Primary biliary cholangitis
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Primary biliary cholangitis
    • 5.7.3. Sub-Type Specific cases of the Primary biliary cholangitis *
    • 5.7.4. Sex- Specific Cases of the Primary biliary cholangitis *
    • 5.7.5. Diagnosed Cases of the Primary biliary cholangitis
    • 5.7.6. Treatable Cases of the Primary biliary cholangitis
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Primary biliary cholangitis
    • 5.8.3. Sub-Type Specific cases of the Primary biliary cholangitis *
    • 5.8.4. Sex- Specific Cases of the Primary biliary cholangitis *
    • 5.8.5. Diagnosed Cases of the Primary biliary cholangitis
    • 5.8.6. Treatable Cases of the Primary biliary cholangitis
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Primary biliary cholangitis
    • 5.9.3. Sub-Type Specific cases of the Primary biliary cholangitis *
    • 5.9.4. Sex- Specific Cases of the Primary biliary cholangitis *
    • 5.9.5. Diagnosed Cases of the Primary biliary cholangitis
    • 5.9.6. Treatable Cases of the Primary biliary cholangitis

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Primary biliary cholangitis

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Primary biliary cholangitis

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Primary biliary cholangitis : 7MM Market Analysis

  • 12.1. 7MM Market Size of Primary biliary cholangitis
  • 12.2. 7MM Percentage Share of drugs marketed for Primary biliary cholangitis
  • 12.3. 7MM Market Sales of Primary biliary cholangitis by Products

13. Primary biliary cholangitis : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Primary biliary cholangitis in United States
    • 13.1.2. Percentage Share of drugs marketed for Primary biliary cholangitis in United States
    • 13.1.3. Market Sales of Primary biliary cholangitis by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Primary biliary cholangitis in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Primary biliary cholangitis in Germany
      • 13.2.1.3. Market Sales of Primary biliary cholangitis by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Primary biliary cholangitis in France
      • 13.2.2.2. Percentage Share of drugs marketed for Primary biliary cholangitis in France
      • 13.2.2.3. Market Sales of Primary biliary cholangitis by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Primary biliary cholangitis in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Primary biliary cholangitis in Italy
      • 13.2.3.3. Market Sales of Primary biliary cholangitis by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Primary biliary cholangitis in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Primary biliary cholangitis in Spain
      • 13.2.4.3. Market Sales of Primary biliary cholangitis by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Primary biliary cholangitis in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Primary biliary cholangitis in United Kingdom
      • 13.2.5.3. Market Sales of Primary biliary cholangitis by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Primary biliary cholangitis in Japan
    • 13.3.2. Percentage Share of drugs marketed for Primary biliary cholangitis in Japan
    • 13.3.3. Market Sales of Primary biliary cholangitis by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

Back to Top